Promoter hypermethylation of the EMP3 gene in a series of 229 human gliomas

BioMed Research International

Volumn 2013, Issue , 2013, Pages

  Mellai, Marta ^a   Piazzi, Angela ^a   Caldera, Valentina ^a   Annovazzi, Laura ^a   Monzeglio, Oriana ^a   Senetta, Rebecca ^b   Cassoni, Paola ^b   Schiffer, Davide ^a  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF TURIN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ISOCITRATE DEHYDROGENASE 1; ISOCITRATE DEHYDROGENASE 2; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; PROTEIN P53; TEMOZOLOMIDE; DNA LIGASE; DNA METHYLTRANSFERASE; EGFR PROTEIN, HUMAN; EMP3 PROTEIN, HUMAN; MEMBRANE PROTEIN; MGMT PROTEIN, HUMAN; TUMOR MARKER; TUMOR SUPPRESSOR PROTEIN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE;

ADOLESCENT; ADULT; AGED; ARTICLE; ASTROCYTOMA; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CAPILLARY ELECTROPHORESIS; CHILD; CPG ISLAND; DNA METHYLATION; EPITHELIAL MEMBRANE PROTEIN 3; FEMALE; GENE AMPLIFICATION; GENE DELETION; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MISSENSE MUTATION; MULTIPLEX LIGATION DEPENDENT PROBE AMPLIFICATION; NUCLEOTIDE SEQUENCE; OLIGODENDROGLIA; OLIGODENDROGLIOMA; OVERALL SURVIVAL; PILOCYTIC ASTROCYTOMA; POINT MUTATION; PRIMARY TUMOR; PROMOTER REGION; PROTEIN EXPRESSION; SCHOOL CHILD; TRANSCRIPTION INITIATION SITE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING; BRAIN TUMOR; CHROMOSOME 1; CHROMOSOME 19; DNA MUTATIONAL ANALYSIS; GENETICS; METABOLISM; MIDDLE AGED; MOLECULAR GENETICS; PATHOLOGY; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT; SURVIVAL;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BASE SEQUENCE; BIOMARKERS, TUMOR; BRAIN NEOPLASMS; CHILD; CHROMOSOMES, HUMAN, PAIR 1; CHROMOSOMES, HUMAN, PAIR 19; CPG ISLANDS; DNA METHYLATION; DNA MODIFICATION METHYLASES; DNA MUTATIONAL ANALYSIS; DNA REPAIR ENZYMES; FEMALE; GENE AMPLIFICATION; GLIOMA; HUMANS; MALE; MEMBRANE GLYCOPROTEINS; MIDDLE AGED; MOLECULAR SEQUENCE DATA; PROMOTER REGIONS, GENETIC; RECEPTOR, EPIDERMAL GROWTH FACTOR; SURVIVAL ANALYSIS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; YOUNG ADULT; TUMOR MARKERS, BIOLOGICAL;

EID: 84884833048     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2013/756302     Document Type: Article

References (39)

1. Taylor V., Welcher A. A., Program A. E., Suter U., Epithelial membrane protein-1, peripheral myelin protein 22, and lens membrane protein 20 define a novel gene family. The Journal of Biological Chemistry 1995 270 48 28824 28833 2-s2.0-0028793694 10.1074/jbc.270.48.28824
2. Taylor V., Suter U., Epithelial membrane protein-2 and epithelial membrane protein-3: two novel members of the peripheral myelin protein 22 gene family. Gene 1996 175 1-2 115 120 2-s2.0-0030579151 10.1016/0378-1119(96)00134-5 (Pubitemid 26363007)
3. Ben-Porath I., Benvenisty N., Characterization of a tumor-associated gene, a member of a novel family of genes encoding membrane glycoproteins. Gene 1996 183 1-2 69 75 2-s2.0-0030461764 10.1016/S0378-1119(96)00475-1 (Pubitemid 27011681)
4. Liehr T., Kuhlenbäumer G., Wulf P., Taylor V., Suter U., Van Broeckhoven C., Lupski J. R., Claussen U., Rautenstrauss B., Regional localization of the human epithelial membrane protein genes 1, 2, and 3 (EMP1, EMP2, EMP3) to 12p12.3, 16p13.2, and 19q13.3. Genomics 1999 58 1 106 108 2-s2.0-0345518007 10.1006/geno.1999.5803 (Pubitemid 29269888)
5. Alaminos M., Dávalos V., Ropero S., Setién F., Paz M. F., Herranz M., Fraga M. F., Mora J., Cheung N.-K. V., Gerald W. L., Esteller M., EMP3, a myelin-related gene located in the critical 19q13.3 region, is epigenetically silenced and exhibits features of a candidate tumor suppressor in glioma and neuroblastoma. Cancer Research 2005 65 7 2565 2571 2-s2.0-20144387913 10.1158/0008-5472.CAN-04-4283 (Pubitemid 40490052)
6. Tews B., Felsberg J., Hartmann C., Kunitz A., Hahn M., Toedt G., Neben K., Hummerich L., Von Deimling A., Reifenberger G., Lichter P., Identification of novel oligodendroglioma-associated candidate tumor suppressor genes in 1p36 and 19q13 using microarray-based expression profiling. International Journal of Cancer 2006 119 4 792 800 2-s2.0-33745890593 10.1002/ijc.21901 (Pubitemid 44051441)
7. Kunitz A., Wolter M., van den Boom J., Felsberg J., Tews B., Hahn M., Benner A., Sabel M., Lichter P., Reifenberger G., Von Deimling A., Hartmann C., DNA hypermethylation and aberrant expression of the EMP3 gene at 19q13.3 in human gliomas. Brain Pathology 2007 17 4 363 370 2-s2.0-35148825960 10.1111/j.1750-3639.2007.00083.x (Pubitemid 47537593)
8. Li K. K. W., Pang J. C.-S., Chung N. Y.-F., Ng Y. L., Chan N. H. L., Zhou L., Poon W. S., Ng H.-K., EMP3 overexpression is associated with oligodendroglial tumors retaining chromosome arms 1p and 19q. International Journal of Cancer 2007 120 4 947 950 2-s2.0-33846617717 10.1002/ijc.22415 (Pubitemid 46175419)
9. Margetts C. D. E., Morris M., Astuti D., Gentle D. C., Cascon A., McRonald F. E., Catchpoole D., Robledo M., Neumann H. P. H., Latif F., Maher E. R., Evaluation of a functional epigenetic approach to identify promoter region methylation in phaeochromocytoma and neuroblastoma. Endocrine-Related Cancer 2008 15 3 777 786 2-s2.0-53849146718 10.1677/ERC-08-0072
10. Fumoto S., Tanimoto K., Hiyama E., Noguchi T., Nishiyama M., Hiyama K., EMP3 as a candidate tumor suppressor gene for solid tumors. Expert Opinion on Therapeutic Targets 2009 13 7 811 822 2-s2.0-67650448193 10.1517/ 14728220902988549
11. Fumoto S., Hiyama K., Tanimoto K., Noguchi T., Hihara J., Hiyama E., Noguchi T., Nishiyama M., EMP3 as a tumor suppressor gene for esophageal squamous cell carcinoma. Cancer Letters 2009 274 1 25 32 2-s2.0-57749090287 10.1016/j.canlet.2008.08.021
12. Zhou W., Jiang Z., Li X., Xu F., Liu Y., Wen P., Kong L., Hou M., Yu J., EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations. Journal of Korean Medical Science 2009 24 1 97 103 2-s2.0-65649121834 10.3346/jkms.2009.24.1.97
13. Jiang Z., Zhou W., Li X.-G., Jiang Y.-Q., Wang L., Wang D.-H., Wang X.-Y., Li X.-E., The methylation analysis of EMP3 and PCDH-gamma-A11 gene in human glioma. Zhonghua Wai Ke Za Zhi 2010 48 4 300 304 2-s2.0-79952115849
14. Scrideli C. A., Carlotti C. G. Jr., Okamoto O. K., Andrade V. S., Cortez M. A. A., Motta F. J. N., Lucio-Eterovic A. K., Neder L., Rosemberg S., Oba-Shinjo S. M., Marie S. K. N., Tone L. G., Gene expression profile analysis of primary glioblastomas and non-neoplastic brain tissue: identification of potential target genes by oligonucleotide microarray and real-time quantitative PCR. Journal of Neuro-Oncology 2008 88 3 281 291 2-s2.0-44649135084 10.1007/s11060-008-9579-4
15. Ernst A., Hofmann S., Ahmadi R., Becker N., Korshunov A., Engel F., Hartmann C., Felsberg J., Sabel M., Peterziel H., Durchdewald M., Hess J., Barbus S., Campos B., Starzinski-Powitz A., Unterberg A., Reifenberger G., Lichter P., Herold-Mende C., Radlwimmer B., Genomic and expression profiling of glioblastoma stem cell-like spheroid cultures identifies novel tumor-relevant genes associated with survival. Clinical Cancer Research 2009 15 21 6541 6550 2-s2.0-70350741358 10.1158/1078-0432.CCR-09-0695
16. Zheng S., Houseman E. A., Morrison Z., Wrensch M. R., Patoka J. S., Ramos C., Haas-Kogan D. A., McBride S., Marsit C. J., Christensen B. C., Nelson H. H., Stokoe D., Wiemels J. L., Chang S. M., Prados M. D., Tihan T., Vandenberg S. R., Kelsey K. T., Berger M. S., Wiencke J. K., DNA hypermethylation profiles associated with glioma subtypes and EZH2 and IGFBP2 mRNA expression. Neuro-Oncology 2011 13 3 280 289 2-s2.0-79955765058 10.1093/neuonc/noq190
17. Pasini A., Iorio P., Bianchi E., LOH 19q indicates shorter disease progression-free interval in low-grade oligodendrogliomas with EMP3 methylation. Oncology Reports 2012 28 6 2271 2277
18. Louis D. N., Ohgaki H., Wiestler O. D., WHO Classification of Tumors of the Central Nervous Systems 2007 4th Lyon, France International Agency for Research on Cancer (IARC)
19. Mellai M., Caldera V., Annovazzi L., Chiò A., Lanotte M., Cassoni P., Finocchiaro G., Schiffer D., MGMT promoter hypermethylation in a series of 104 glioblastomas. Cancer Genomics and Proteomics 2009 6 4 219 227 2-s2.0-69549111318
20. Esteller M., Hamilton S. R., Burger P. C., Baylin S. B., Herman J. G., Inactivation of the DNA repair gene O(6)-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Research 1999 59 4 793 797 2-s2.0-0033557903 (Pubitemid 29086728)
21. Mellai M., Monzeglio O., Piazzi A., Caldera V., Annovazzi L., Cassoni P., Valente G., Cordera S., Mocellini C., Schiffer D., MGMT promoter hypermethylation and its associations with genetic alterations in a series of 350 brain tumors. Journal of Neuro-Oncology 2012 107 3 617 631 2-s2.0-84856111175 10.1007/s11060-011-0787-y
22. Mellai M., Piazzi A., Caldera V., Monzeglio O., Cassoni P., Valente G., Schiffer D., IDH1 and IDH2 mutations, immunohistochemistry and associations in a series of brain tumors. Journal of Neuro-Oncology 2011 105 2 345 357 2-s2.0-82955165744 10.1007/s11060-011-0596-3
23. Caldera V., Mellai M., Annovazzi L., Piazzi A., Lanotte M., Cassoni P., Schiffer D., Antigenic and genotypic similarity between primary glioblastomas and their derived neurospheres. Journal of Oncology 2011 2011 16 2-s2.0-80053498379 10.1155/2011/314962 314962
24. Mellai M., Caldera V., Annovazzi L., Schiffer D., Lichtor T., The distribution and significance of IDH mutations in gliomas. Evolution of the Molecular Biology of Brain Tumors and Therapeutic Implications 2013 Rjieka, Croatia InTech 299 342
25. Noushmehr H., Weisenberger D. J., Diefes K., Phillips H. S., Pujara K., Berman B. P., Pan F., Pelloski C. E., Sulman E. P., Bhat K. P., Verhaak R. G. W., Hoadley K. A., Hayes D. N., Perou C. M., Schmidt H. K., Ding L., Wilson R. K., Van Den Berg D., Shen H., Bengtsson H., Neuvial P., Cope L. M., Buckley J., Herman J. G., Baylin S. B., Laird P. W., Aldape K., Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 2010 17 5 510 522 2-s2.0-77952108366 10.1016/j.ccr.2010.03.017
26. Malzkorn B., Wolter M., Riemenschneider M. J., Reifenberger G., Unraveling the glioma epigenome-from molecular mechanisms to novel biomarkers and therapeutic targets. Brain Pathology 2011 21 6 619 632 2-s2.0-80054708001 10.1111/j.1750-3639.2011.00536.x
27. Christensen B. C., Smith A. A., Zheng S., Koestler D. C., Houseman E. A., Marsit C. J., Wiemels J. L., Nelson H. H., Karagas M. R., Wrensch M. R., Kelsey K. T., Wiencke J. K., DNA methylation, isocitrate dehydrogenase mutation, and survival in glioma. Journal of the National Cancer Institute 2011 103 2 143 153 2-s2.0-79251470741 10.1093/jnci/djq497
28. Laffaire J., Everhard S., Idbaih A., Crinière E., Marie Y., De Reyniès A., Schiappa R., Mokhtari K., Hoang-Xuan K., Sanson M., Delattre J.-Y., Thillet J., Ducray F., Methylation profiling identifies 2 groups of gliomas according to their tumorigenesis. Neuro-Oncology 2011 13 1 84 98 2-s2.0-79951611375 10.1093/neuonc/noq110
29. Turcan S., Rohle D., Goenka A., Walsh L. A., Fang F., Yilmaz E., Campos C., Fabius A. W. M., Lu C., Ward P. S., Thompson C. B., Kaufman A., Guryanova O., Levine R., Heguy A., Viale A., Morris L. G. T., Huse J. T., Mellinghoff I. K., Chan T. A., IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype. Nature 2012 483 7390 479 483 2-s2.0-84858796263 10.1038/nature10866
30. van den Bent M. J., Gravendeel L. A., Gorlia T., Kros J. M., Lapre L., Wesseling P., Teepen J. L., Idbaih A., Sanson M., Sillevis Smitt P. A. E., French P. J., A hypermethylated phenotype is a better predictor of survival than MGMT methylation in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Clinical Cancer Research 2011 17 22 7148 7155 2-s2.0-81255128997 10.1158/1078-0432.CCR-11-1274
31. Felsberg J., Thon N., Eigenbrod S., Hentschel B., Sabel M. C., Westphal M., Schackert G., Kreth F. W., Pietsch T., Löffler M., Weller M., Reifenberger G., Tonn J. C., Promoter methylation and expression of MGMT and the DNA mismatch repair genes MLH1, MSH2, MSH6 and PMS2 in paired primary and recurrent glioblastomas. International Journal of Cancer 2011 129 3 659 670 2-s2.0-79958072588 10.1002/ijc.26083
32. Ohgaki H., Schauble B., zur Hausen A., von Ammon K., Kleihues P., Genetic alterations associated with the evolution and progression of astrocytic brain tumours. Virchows Archiv 1995 427 2 113 118 2-s2.0-0028882666
33. Mora J., Cheung N.-K. V., Chen L., Qin J., Gerald W., Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clinical Cancer Research 2001 7 5 1358 1361 2-s2.0-0034907626 (Pubitemid 32708692)
34. Bettegowda C., Agrawal N., Jiao Y., Sausen M., Wood L. D., Hruban R. H., Rodriguez F. J., Cahill D. P., McLendon R., Riggins G., Velculescu V. E., Oba-Shinjo S. M., Marie S. K. N., Vogelstein B., Bigner D., Yan H., Papadopoulos N., Kinzler K. W., Mutations in CIC and FUBP1 contribute to human oligodendroglioma. Science 2011 333 6048 1453 1455 2-s2.0-80052608062 10.1126/science.1210557
35. Yip S., Butterfield Y. S., Morozova O., Chittaranjan S., Blough M. D., An J., Birol I., Chesnelong C., Chiu R., Chuah E., Corbett R., Docking R., Firme M., Hirst M., Jackman S., Karsan A., Li H., Louis D. N., Maslova A., Moore R., Moradian A., Mungall K. L., Perizzolo M., Qian J., Roldan G., Smith E. E., Tamura-Wells J., Thiessen N., Varhol R., Weiss S., Wu W., Young S., Zhao Y., Mungall A. J., Jones S. J. M., Morin G. B., Chan J. A., Cairncross J. G., Marra M. A., Concurrent CIC mutations, IDH mutations, and 1p/19q loss distinguish oligodendrogliomas from other cancers. Journal of Pathology 2012 226 1 7 16 2-s2.0-82755194965 10.1002/path.2995
36. Sahm F., Koelsche C., Meyer J., CIC and FUBP1 mutations in oligodendrogliomas, oligoastrocytomas and astrocytomas. Acta Neuropathologica 2012 123 6 853 860
37. Yan H., Parsons D. W., Jin G., McLendon R., Rasheed B. A., Yuan W., Kos I., Batinic-Haberle I., Jones S., Riggins G. J., Friedman H., Friedman A., Reardon D., Herndon J., Kinzler K. W., Velculescu V. E., Vogelstein B., Bigner D. D., IDH1 and IDH2 mutations in gliomas. The New England Journal of Medicine 2009 360 8 765 773 2-s2.0-60849115270 10.1056/NEJMoa0808710
38. van den Bent M. J., Dubbink H. J., Marie Y., Brandes A. A., Taphoorn M. J. B., Wesseling P., Frenay M., Tijssen C. C., Lacombe D., Idbaih A., Van Marion R., Kros J. M., Dinjens W. N. M., Gorlia T., Sanson M., IDH1 and IDH2 mutations are prognostic but not predictive for outcome in anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor Group. Clinical Cancer Research 2010 16 5 1597 1604 2-s2.0-77649122144 10.1158/1078-0432.CCR-09-2902
39. Colman H., Zhang L., Sulman E. P., McDonald J. M., Shooshtari N. L., Rivera A., Popoff S., Nutt C. L., Louis D. N., Cairncross J. G., Gilbert M. R., Phillips H. S., Mehta M. P., Chakravarti A., Pelloski C. E., Bhat K., Feuerstein B. G., Jenkins R. B., Aldape K., A multigene predictor of outcome in glioblastoma. Neuro-Oncology 2010 12 1 49 57 2-s2.0-75749115909 10.1093/neuonc/nop007